New Treatment Concept

The Problem: 

In 2018, it is expected that over 620,000 Americans will die of cancer. Cancer is the second most common cause of death in the US after heart disease. Compared to the economic impact of premature death and disability of all causes of death, cancer has the greatest cost worldwide.

As a person’s cells accumulate mutations due to a combination of environmental and genetic factors, rapid cell growth can occur.  If the immune system is unable to recognize and kill those mutated cells, tumors can begin to form.  When those tumors reach a certain size, they can shed cells that spread throughout the body. Left undetected, those cells grow and soon the person has late-stage cancer consisting of large, well-defined tumors and small unseen groups of cells or micro-metastases. These metastases can exist either in the blood or body tissue.  Cancer is thus a regional and systemic disease. To be effective against such a difficult disease a treatment must destroy both the visible tumors as well as the unseen metastases.

Today’s best approaches

A combination of local treatment (surgery, radiation, ablation) coupled with systemic chemo- targeted or immune regulating therapies given orally or intravenously (IV) are the most common methods to treat cancer today. Unfortunately, in later disease these therapies have only a small effect on outcomes for the majority of cancer patients (Morgan (Clinical Oncology (R Coll Radiol) 2004 Dec;16(8):549-60). The lack of therapeutic efficacy for systemically administered drugs may be due in large part to the low levels of drug reaching the tumor sites.  In addition, once at the tumor the drug may not be able to reach all the cancer cells in a tumor. Systemic drug concentrations most often are insufficient for tumor destruction if a patient has several large, visible lesions.  In the case of the new immunotherapies, the problem may be recognition of the cancer by the immune cells.

Even with good treatment outcomes, whether surgical, chemical, radiation, ablation methods, or immune-based these techniques remain invasive, have severe side effects that damage the body and are demanding on the patient. The reality today is that if cancer is detected late, most treatments are highly toxic and few provide patients with much hope of long term survival.

Our Solution

Cancer cells need to absorb nutrients at a high rate. As a result, cancer cell membranes are more fluid than those of normal tissue. Our products are injected directly into tumors. Our technology improves drug dispersion throughout a tumor and increases the diffusion of potent drug agents directly into cancer cells.  This results in a more complete tumor death and the creation of high quality, personalized antigen that helps the immune system to recognize the cancer.  Once trained and engaged the immune system attacks the uninjected tumors and metastases to control or kill the cancer.  Our product thus has a dual mechanism of action – direct tumor killing to create better signals for more specific anti-cancer immune activation.

Back to Technology
Back to Top